Other Events ·
At its annual meeting on June 5, 2026, Inogen, Inc. stockholders approved the Amended and Restated 2023 Equity…
INGNInogen Inc
At its annual meeting on June 5, 2026, Inogen, Inc. stockholders approved the Amended and Restated 2023 Equity Incentive Plan, which increases the number of common shares available for issuance by 750,000. Shareholders also elected Glenn Boehnlein and Mira Sahney as Class III directors and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year. An advisory vote on executive compensation was approved, but a proposal to declassify the Board of Directors failed to pass. Inogen, Inc. develops and markets portable oxygen concentrators for medical use.